Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration

Status Completed

Clinical Trial Summary

The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma

2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose

3. the effects of nadroparin during critical illness on coagulation and anticoagulation

Clinical Trial Description

The low molecular weight heparin (LMWH) nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. LMWH accumulate in patients with chronic renal failure. Continuous venovenous hemofiltration (CVVH) is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. If not, accumulation is expected and the risk of bleeding for the patient increases. Because critically ill patients are at increased risk of bleeding, this question is crucial.

If nadroparin would be removed by filtration, removal is expected to depend on hemofiltration dose (to be greater with a higher dose)

We therefore designed a randomized controlled cross-over trial in the setting of critical illness and acute renal failure comparing the anticoagulant effect of nadroparin (anti-Xa) between two doses of CVVH in the patients blood, in the extracorporeal circuit and in the ultrafiltrate.

Because hemostasis in critically ill patients is not only influenced by anticoagulation but also by the critical illness and the extracorporeal circuit, we also measure other hemostatic markers, especially the endogenous thrombin potential (ETP), which seems the most global marker of hemostasis, incorporating procoagulant and anticoagulant effects. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00965328
Study type	Interventional
Source	Onze Lieve Vrouwe Gasthuis
Contact
Status	Completed
Phase	Phase 4
Start date	February 2007
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01946113` - Mineral-Homeostasis in Continuous Renal Replacement Therapy	N/A
Withdrawn	`NCT00993733` - Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care	N/A
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Terminated	`NCT00978354` - Furosemide in Early Acute Kidney Injury	Phase 2/Phase 3
Completed	`NCT00120263` - Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma	N/A
Completed	`NCT04799600` - The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Recruiting	`NCT04334707` - Kidney Precision Medicine Project
Completed	`NCT02858531` - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Recruiting	`NCT05282732` - Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01979042` - Urinary Markers for Unilateral Kidney Obstruction	N/A
Completed	`NCT01280617` - Low Dose Thymoglobin in Renal Transplant Patients	N/A
Completed	`NCT00780351` - Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)	N/A
Completed	`NCT00971971` - Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients	N/A
Completed	`NCT00076219` - Acute Renal Failure Trial Network (ATN) Study	Phase 3
Recruiting	`NCT04599569` - Influence of Renal Replacement TherApy on Indirect Calorimetry
Completed	`NCT03727204` - Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
Completed	`NCT06005896` - A Clinical Model for Dialysis Discontinuation in AKI
Completed	`NCT03004950` - Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
Completed	`NCT03627884` - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.